| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 217.34 | 2.4% |
| Total Income | 225.83 | 1.9% |
| Expenditure | 203.38 | 0.5% |
| PBT | 22.45 | 13.3% |
| Net Profit | 20.77 | 23.7% |
| OPM | 0.72% | 2.17pp |
| NPM | 9.94% | 1.31pp |
| EPS | 4.10 | 23.6% |
Orchid Pharma continues on a steady growth path with strengthening market position: Q3 results show strong momentum with 26% PAT growth in YoY-9 month backed by expansion of its anti-microbial portfolio
13 Feb 2025 · 13 Feb 2025, 12:01 am
Summary
Orchid Pharma Ltd., a vertically integrated pharmaceutical company, has announced its Q3 financial results for FY 2024-25, reporting a 26% year-on-year increase in Profit After Tax (PAT) in YoY-9 month. This growth is attributed to the strategic execution and ongoing expansion efforts, particularly in the Anti-Microbial Stewardship (AMS) division. The AMS division has contributed significantly to the company’s performance and is poised to drive future growth.
Key Highlights
- 1
26% YoY increase in PAT in YoY-9 month
- 2
Expansion of Anti-Microbial Stewardship (AMS) division
- 3
Strategic execution and ongoing expansion efforts
- 4
Robust product pipeline and strategic R&D investments
- 5
Dedicated to addressing global healthcare challenges through innovation
Management Comments
Manish Dhanuka
We believe that our commitment to innovation and operational excellence will yield positive results. The AMS division is progressing as expected, and we are confident in its potential to drive future growth. Our focus remains on developing specialized solutions, such as our novel drug Enmetazobactam, and enhancing market reach with ORBLICEF, launched in partnership with Cipla. With a robust product pipeline and strategic R&D investments, we are well- positioned to accelerate growth in the coming quarters.
Informational and educational content only. Not investment advice.